Clinical Trial Update: Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial of cabozantinib in non-small cell lung cancer with brain metastases was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Liza Villaruz, MD | Conditions: Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain | Phase 2 | Status: TERMINATED | Results posted: 2020-09-16